

Carasent - Solid ARR despite lowered target

Redeye updates its Base Case and forecasts following the Q2 report, showing solid underlying business momentum despite the lowered 2025 target.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Carasent - Solid ARR despite lowered target